Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266145 | 0.85 | ALDH1A1 (0.37) | ALDH1A1KDM4EL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1267506 | 0.85 | ALDH1A1 (0.36) | ALDH1A1KDM4EL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1267514 | 0.84 | ALDH1A1 (0.36) | ALDH1A1KDM4EL3MBTL1MAPTHPGD | |
| SCHEMBL1266013 | 0.84 | ALDH1A1 (0.35) | ALDH1A1KDM4EL3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL2420285 | 0.74 | — | — | |
| SCHEMBL2420495 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1266883 | 0.71 | ALDH1A1 (1.00) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL1266997 | 0.68 | ALDH1A1 (0.72) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL1267125 | 0.67 | ALDH1A1 (0.72) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT | |
| SCHEMBL1266133 | 0.65 | ALDH1A1 (0.70) | ALDH1A1KDM4EL3MBTL1CHRNA7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879858-B2 | monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics | GRUENENTHAL GMBH (DE) | 2011-02-01 | — | — | US | claimed |
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | US | claimed |
| US-7879858-B2 | monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics | GRUENENTHAL GMBH (DE) | 2011-02-01 | — | — | US | disclosed |
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | GRUENENTHAL GMBH (DE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258880-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions | DHPS, APC, CYP3A5 | ALDH1A1 559/4885KDM4E 2341/4885L3MBTL1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.